Müller R, Baumgarten R, Markus R, Schulz M, Wittenberg H, Hintsche-Kilger B, Fengler J D, von Wussow P, Meisel H, Klein H
Abteilung für Gastroenterologie und Hepatologie, Medizinische Hochschule Hannover, Germany.
Gut. 1993;34(2 Suppl):S97-8. doi: 10.1136/gut.34.2_suppl.s97.
Fifty eight patients with chronic viral hepatitis B (HBV) were randomised in a prospectively controlled trial. Thirty patients were treated with 3 million units (MU) of interferon alfa-2b subcutaneously thrice weekly for four months. Twenty eight controls received no treatment. The follow up period after treatment was six months. Twenty eight treated patients and 27 controls completed the protocol. One woman in the treatment group showed a complete response, and eight other treated patients (32%) showed a partial response. Three patients in the control group (11%) lost hepatitis B e antigen and HBV-DNA spontaneously. This finding is statistically significant (p < 0.05). The elimination of HBV markers from the serum was associated with a return to normal of serum aminotransferase activities. Reactivation of hepatitis was not observed after seroconversion.
58例慢性乙型肝炎病毒（HBV）患者被随机纳入一项前瞻性对照试验。30例患者接受300万单位（MU）的α-2b干扰素皮下注射，每周3次，共4个月。28例对照未接受治疗。治疗后的随访期为6个月。28例治疗患者和27例对照完成了方案。治疗组中有1名女性显示完全缓解，其他8例治疗患者（32%）显示部分缓解。对照组中有3例患者（11%）自发丢失乙肝e抗原和HBV-DNA。这一发现具有统计学意义（p<0.05）。血清中HBV标志物的消除与血清转氨酶活性恢复正常有关。血清学转换后未观察到肝炎再激活。
